Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Lancet Neurol. 2013 Sep 4;12(10):957–965. doi: 10.1016/S1474-4422(13)70194-7

Table 1.

Glossary of preclinical AD stages and symptomatic AD

Normal group CDR 01, amyloid (−), neural injury (−), subtle cognitive decline (−)
Preclinical AD stage 1 CDR 0, amyloid (+)2, neural injury (−), subtle cognitive decline (−)
Preclinical AD stage 2 CDR 0, amyloid (+), neural injury (+)3, subtle cognitive decline (−)
Preclinical AD stage 3 CDR 0, amyloid (+), neural injury (+), subtle cognitive decline (+)4
SNAP group5 CDR 0, amyloid (−), neural injury (+), subtle cognitive decline (−/+)
Unclassified group CDR 0, amyloid (−/+), neural injury (−), subtle cognitive decline (+)
Symptomatic AD CDR>06, memory and at least one other domain received a score of
≥0·5 and the clinician felt the cognitive impairments to be due to AD
(probable AD), no reference to biomarkers
1

CDR 0, Clinical Dementia Rating=0, no dementia

2

Amyloid, CSF Aβ42 (+) <459pg/mL

3

Neural injury, CSF tau (+) >339pg/mL or ptau 181 (+) >67pg/mL

4

Subtle cognitive decline, episodic memory composite score (+) in the lowest 10th percentile

5

SNAP, Suspected Non-Alzheimer Pathophysiology

6

CDR>0, CDR 0·5= very mild dementia, CDR 1=mild dementia, CDR 2=moderate dementia, CDR 3=severe dementia